Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of “Hold” from Analysts


Share on StockTwits

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have earned an average rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $21.67.

A number of research firms have issued reports on AMPH. Wells Fargo & Company reduced their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 23rd. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 17th.

In related news, CEO Jack Y. Zhang sold 19,823 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, February 11th. The shares were sold at an average price of $19.06, for a total value of $377,826.38. Following the sale, the chief executive officer now owns 2,246,988 shares of the company’s stock, valued at approximately $42,827,591.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO William J. Peters sold 4,244 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, March 15th. The shares were sold at an average price of $19.03, for a total transaction of $80,763.32. Following the completion of the sale, the chief financial officer now directly owns 85,304 shares in the company, valued at approximately $1,623,335.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 120,990 shares of company stock valued at $2,281,552. Insiders own 29.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Sei Investments Co. boosted its stake in Amphastar Pharmaceuticals by 27.9% during the 3rd quarter. Sei Investments Co. now owns 89,658 shares of the company’s stock worth $1,681,000 after purchasing an additional 19,564 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Amphastar Pharmaceuticals by 4.8% during the 4th quarter. Exchange Traded Concepts LLC now owns 16,565 shares of the company’s stock worth $333,000 after purchasing an additional 756 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Amphastar Pharmaceuticals by 100.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 34,964 shares of the company’s stock worth $703,000 after purchasing an additional 17,542 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Amphastar Pharmaceuticals by 8.4% during the 4th quarter. Victory Capital Management Inc. now owns 13,572 shares of the company’s stock worth $273,000 after purchasing an additional 1,050 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in Amphastar Pharmaceuticals during the 4th quarter worth $698,000. 55.08% of the stock is currently owned by hedge funds and other institutional investors.

AMPH traded up $0.30 during trading on Tuesday, reaching $17.79. 1,431 shares of the company’s stock were exchanged, compared to its average volume of 189,831. Amphastar Pharmaceuticals has a 1 year low of $16.54 and a 1 year high of $22.69. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.86 and a quick ratio of 1.73. The stock has a market capitalization of $848.41 million, a P/E ratio of 126.50 and a beta of 0.87. The company’s fifty day simple moving average is $17.78 and its 200-day simple moving average is $18.70.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Sunday, March 14th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Amphastar Pharmaceuticals had a net margin of 1.97% and a return on equity of 5.50%. The company had revenue of $95.92 million during the quarter, compared to analyst estimates of $89.29 million. Equities analysts forecast that Amphastar Pharmaceuticals will post 0.38 EPS for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Featured Article: Why do companies issue monthly dividends?

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.